Co-treatment with copper compounds dramatically decreases toxicities observed with Cisplatin cancer therapy and the anticancer efficacy of some copper chelates supports the conclusion that copper chelate therapy may be markedly more effective and less toxic than Cisplatin therapy

Current Medicinal Chemistry

Volumn 14, Issue 14, 2007, Pages 1499-1503

  Sorenson, John R J ^a,b   Wangila, Grant W ^b  

^a UNIVERSITY OF ARKANSAS AT LITTLE ROCK   (United States)

^b UNIVERSITY OF ARKANSAS AT PINE BLUFF   (United States)

Author keywords

Ammonium tetrathiomolybdate; Androstenedione synthesis; Anti inflammatory; Anticancer; Cisplatin; Copper chelates; Coppertetrathiomolybdate; Redifferentiation

Indexed keywords

3,5 DI TERT BUTYL SALICYLATE COPPER; 3,5 DIISOPROPYLSALICYLATE COPPER; ANTIOXIDANT; CASPASE 3; CISPLATIN; COPPER DERIVATIVE; COPPER SULFATE; COPPER ZINC SUPEROXIDE DISMUTASE; METALLOTHIONEIN; PROTEIN BAX; SALICYLIC ACID DERIVATIVE; TETRATHIOMOLYBDATE AMMONIUM; UNCLASSIFIED DRUG;

ACUTE KIDNEY TUBULE NECROSIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BLADDER CANCER; BONE MARROW DEPRESSION; BONE MARROW DISEASE; BREAST ADENOCARCINOMA; CANCER CELL CULTURE; CANCER INHIBITION; CANCER SURVIVAL; CANCER TRANSPLANTATION; CELL DIFFERENTIATION; CELL KILLING; CREATININE BLOOD LEVEL; DISEASE MODEL; DRUG ACTIVITY; DRUG EFFICACY; DRUG FATALITY; DRUG POTENCY; DRUG STRUCTURE; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME SYNTHESIS; GASTROINTESTINAL DISEASE; HEAD AND NECK CANCER; HUMAN; KIDNEY DISEASE; KIDNEY TUBULE DAMAGE; LEWIS CARCINOMA; LIPOPHILICITY; LUNG SMALL CELL CANCER; NECROTIZING ENTERITIS; NEUROBLASTOMA CELL; NONHUMAN; OSTEOSARCOMA; OVARY CANCER; PIGEON; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; TESTIS CANCER; THYMUS ATROPHY; THYMUS DISEASE; UREA NITROGEN BLOOD LEVEL; VOMITING;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CHELATING AGENTS; CISPLATIN; COPPER; HUMANS; MOLYBDENUM; NEOPLASMS; ORGANOMETALLIC COMPOUNDS;

EID: 34250367699     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986707780831041     Document Type: Review

References (49)

1. Gonzalez-Vitale, J.C.; Hayes, D.M.; Cvitkovic, E.; Sternberg, S.S. Cancer, 1976, 39, 1362.
2. Ward, J.M.; Fauvie, K.A. Tox. Appl. Pharmacol, 1976, 38, 535.
3. Sharma, R.P.; Edwards, I.R. Biochem. Pharmacol., 1983, 32 2665.
4. Mason, R.; Edwards, I.R.; McLaren, S. Chem-Biol. Interact., 1984, 49, 165.
5. Mason, R.W.; Edwards, I.R. Biochem. Pharmacol., 1985, 34, 2575.
6. Mason, R.W.; Edwards, I.R. Toxicology, 1985, 37, 267.
7. Naganuma, A.; Satoh, M.; Imura, N. Cancer Res., 1987, 47, 983.
8. Zelazowski, A.J.; Garvey, J.S.; Hoeschele, J.D. Arch. Biochem. Biophys., 1984, 229, 246.
9. Naganuma, A.; Satoh, M.; Koyama, Y.; Imura, N. Toxicol. Lett., 1985, 24, 203.
10. Bongers, J.; Bell, J.U.; Richardson, D.E. J. Inorg. Biochem., 1988, 34, 55.
11. Satoh, M.; Naganuma, A.; Imura, N. Cancer Chemother. Pharmacol., 1988, 21, 176.
12. Kelley, S.L.; Basu, A.; Teicher, B.A.; Hacker, M.P.; Hamer, D.H.; Lazo, J.S. Science, 1998, 241, 1813.
13. Boogaard, P.J.; Slikkerveer, A.; Nagelkerke, J.F.; Mulder, G.J. Biochem. Pharmacol., 1991, 41, 369.
14. Naganuma, A.; Satoh, M.; Imura, N. Res. Comm. Chem. Pathol. Pharmacol., 1984, 46, 265.
15. Blinco, C.; Chidambaram M.V.; Salari, H.; Bond, K.; Evans, D.T.; Gray, R.A.; Griffey, H.B.; Gilbreth-Tranby, G.S.; Garner-Johnson, B.; Lee, T.; Sorenson, J.R.J. Curr. Med. Chem., 2004, 11, 3007
16. Sorenson, J.R.J. Prog. Med. Chem., 1989, 26, 437
17. Sorenson, J.R.J. Curr. Med. Chem., 2002, 9, 1867.
18. Syrkin, A.B.; Chlenova, E.L. Bull. Exptl. Biol. Med., 1988, 105, 477.
19. Pezeshk, A.; Antholine, W.E.; Petering, D.H. J. Inorg. Biochem., 1987, 31, 283.
20. Sahu, S.K. Effects of Dexamethasone on Neuroblastoma Cell Differentiation, Superoxide Dismutase Activity, and the Possible Role of Negative Oxygen Ion on Cell Differentiation (Doctoral dissertation), University of Iowa, University Microfilms International: Ann Arbor, MI. 1979.
21. Leuthauser, S.W.-H.C. Antitumor Activities of Superoxide Dismutase and Copper Coordination Compounds. (Doctoral dissertation), University of Iowa, University Microfilms International: Ann Arbor, MI 1979.
22. Willingham, W.M.; Sorenson, J.R.J. Trace Elem. Med., 1986, 3, 139.
23. Sorenson, J.R.J. In Copper and Zinc in Inflammatory and Degenerative Diseases, Rainsford, K.D.; Milanino, R.; Sorenson, J.R.J., Eds.; Kluwer Academic Publishers: The Netherlands, 1998; pp. 113-124.
24. Feigenbaum, J.J.; Richmond, S.A.; Weissman, Y.; Mechoulam, R. Eur. J. Pharmacol., 1989, 169, 159.
25. Reeves, P.G.; Noordewier, B.; Sarri, J.T. J. Trace Elem. Electolytes Health Dis., 1990, 4, 11.
26. McGinness, F.E.; Proctor, P.H.; Demopoulos, H.B.; Hokanson, J.A.; Kirkpatrick, D.S. Physiol. Chem. Phys., 1978, 10, 267.
27. Huber, W.; Saifer, M.G.P. In Superoxide and Superoxide Dismutases, Michelson, A.M.; McCord, J.M.; Fridovich, I. Eds.; Academic Press: New York, 1977; pp. 517-536.
28. Menander-Huber, K.B.; Huber, W. In Superoxide and Superoxide Dismutases, Michelson, A.M.; McCord, J.M.; Fridovich, I. Eds.; Academic Press: New York 1977 pp. 537-549.
29. Flohe, L.; Biehl, D.; Hofer, H.; Kadrnka, F.; Kolbel, R.; Puhl, W. In Biological and Clinical Aspects of Superoxide and Superoxide Dismutase; Bannister, W.H.; Bannister, J.V. Eds.; Elsevier/ North-Holland: New York, 1980; pp. 424-430.
30. Grankvist, K.; Marklund, S.; Seklin, J.; Taljedal, I.B. Biochem. J., 1979, 182, 17.
31. Oberley, L.W.; Buettner, G.R. Cancer Res., 1979, 39, 1141.
32. Strange, R.W.; Antonyuk, S.; Hough, M.A.; Doucette, P.A.; Rodriguez, J.A.; Hart, P.J.; Hayward, L.J.; Valentine, J.S.; Hasnain, S.S. J. Mol. Biol., 2003, 328, 877.
33. Çetin, R.; Devrim, E.; Kiliçoǧlu, B.; Avci, A.; Çandir, Ö.; Durak, I.. J. Appl. Toxicol., 2006, 26, 42.
34. Sorenson, J.R.J. In Handbook of Metal-Ligand Interactions in Biological Fluids: Bioinorganic Medicine; Berthon, G. Ed.; Marcel Dekker: New York, 1995; Vol. 2, pp. 1318-1324.
35. Sorenson, J.R.J. In Handbook of Metal-Ligand Interactions in Biological Fluids: Bioinorganic Medicine; Berthon, G. Ed.; Marcel Dekker: New York, 1995; Vol. 2, pp. 1128-1139.
36. Keshavarzian, A.; Haydek, J.; Zabihi, R.; Doria, M.; D'Astice, M.; Sorenson, J.R.J. Dig. Dis. Sci., 1992, 37, 1866
37. Reed, G.A.; Madhu, C. In Biology of Copper Complexes, Sorenson, J.R.J., Ed.; The Humana Press, Inc.: Clifton New Jersey, 1987, pp. 287-298.
38. Baquial, J.G.L.; Sorenson, J.R.J. J. Inorg. Biochem., 1995, 60, 133. (Correction; J. Inorg. Biochem., 1997 68, 233.)
39. Booth, B.L.; Pitters, E.; Mayer, B.; Sorenson, J.R.J. Metal-Based Drugs, 1999, 6, 111.
40. Tavadyan, L.A.; Tonikyan, H.G.; Minasyan, S.H.; Harutyunyan, L.A.; Greenaway, F.T.; Williams, S.; Gray, R.A.; Sorenson, J.R.J. Inorg. Chim. Acta, 2002, 32, 1.
41. Wangila, G.W.; Nagothu, K.K.; Steward III, R.; Bhatt, R.; Iyere, P.A.; Willingham, M.W.; Sorenson, J.R.J.; Shah, S.V.; Portilla, D. Toxicol. In Vitro, 2006, 20, 1300.
42. El-Sayed, I.H.; El-Masry, S.M. Redox Rep., 2003, 8, 47.
43. Brewer, G.J. Exptl. Biol. Med., 2001, 226, 665.
44. Goodman, V.L.; Brewer, G.J.; Merajver, S.D. Curr. Cancer Drug Targets, 2005, 5, 543.
45. Brewer, G.J. Drug Discov. Today, 2005, 10, 1103
46. Brewer, G.J.; Dick R.; Zeng, C.; Hou, G. J. Inorg. Biochem., 2006, 100, 927.
47. Hofseth, L.J.; Ying, L. Biochim. Biophys. Acta, 2006, 1765, 74.
48. Kendall, N.R.; Marsters, P.; Guo, L.; Scaramuzzi, R.J.; Campbell, B.K. J. Endocr., 2006, 189, 455.
49. Sorenson, J.R.J. J. Med Chem., 1976, 19, 135.